MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIV has a total of 24 patent applications. Its first patent ever was published in 2002. It filed its patents most often in Australia, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are DDI PHARMACEUTICALS, MESOBLAST INC and EPEIUS BIOTECHNOLOGIES CORP.
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Measurement | |
#5 | Basic materials chemistry | |
#6 | Environmental technology | |
#7 | Agriculture | |
#8 | Medical technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Enzymes | |
#6 | Climate change adaptation technologies | |
#7 | Animal care | |
#8 | Preservation of human bodies | |
#9 | Analysing materials | |
#10 | Object sterilising |
# | Name | Total Patents |
---|---|---|
#1 | Fan Jian-Qiang | 5 |
#2 | Fehling Hans Joerg | 4 |
#3 | Keller Gordon M | 4 |
#4 | Keller Gordon | 4 |
#5 | Schuchman Edward H | 3 |
#6 | Kouskoff Valerie | 3 |
#7 | Desnick Robert J | 3 |
#8 | Kubo Atsushi | 3 |
#9 | Peter Palese | 2 |
#10 | Yang Lei | 2 |
Publication | Filing date | Title |
---|---|---|
AU2012203441A1 | Mesoderm and definitive endoderm cell populations | |
AU2009228354A1 | Human cardiovascular progenitor cells | |
EP2689783A2 | Growth control microorganisms using gallium compounds | |
AU2006262098A1 | Cardiomyocyte cell populations | |
BR122015032743B1 | Attenuated Influenza Virus of Genetically Engineered Pigs, Immunogenic Formulation, Pharmaceutical Formulation, Uses, and Methods for Producing a Vaccine | |
AU2005206914A1 | Devices and methods for repairing cardiac valves |